Idaho Strategic Resources reports drilling results at Golden Chest

Idaho Strategic Resources (NYSE American: IDR) reported heavy rare earth element and yttrium mineralization at its Diamond Creek project. Surface sampling across four prospects along a 3.2 km lineament averaged about 1.8% TREO with HREO above 2,000 ppm, including over 1,300 ppm yttrium. The Lucky Gem trench averaged 1.5% TREO with ~1,600 ppm yttrium, and drillhole DC 22-8 intersected 11.3 m at 1.5% TREO with ~1,700 ppm yttrium. IDR plans further studies and 2026 exploration.

DeFi Technologies reported Valour's AUM grew 61.2% to $640.2M by September 25, 2026, from $397.2M at Q2 end. Valour launched its first hedge fund, Smart Crypto Fund SP, and continues developing new fund structures. The company held $135M in cash and investments with no debt as of June 30, 2026. CEO Johan Wattenström highlighted focus on converting growth into revenue. Nasdaq granted a 180-day extension to address minimum bid price deficiency.

David Ellison appointed Mattel CEO Ynon Kreiz as co-CEO of Paramount-Warner Bros Discovery. Kreiz is known for cost-cutting and restructuring, aiming to deliver $6 billion in savings. His past roles at Mattel and Endemol showed mixed results. Kreiz will focus on operations, while Ellison oversees strategy. Challenges include antitrust settlement obligations and monetizing IP.

Rio Tinto, the Tasmanian and Australian governments agreed to keep the Bell Bay aluminium smelter operating until 2031. The deal includes a five-year power supply agreement with Hydro Tasmania and a AU$200 million support package. The smelter produces 190,000 tons of aluminium annually and contributes AU$260 million to the local economy. Rio Tinto also recently acquired the Aurukun bauxite project in Queensland.

Lockheed Martin's F-35A fighter jets begin permanent deployment in Finland, marking their operational introduction as Finland upgrades its air force and expands NATO role. The first two aircraft arrived in the country, according to the report.

Nektar Therapeutics (NKTR) shares fell after mid-stage trial data for its hair loss drug rezpegaldesleukin was released, showing results from the REZOLVE-AA trial. The stock neared an eight-month low. The drug is being tested as a late-line treatment option.